| Gender |
|
| female | 201 (48.4%) |
| male | 214 (51.6%) |
| Age group |
|
| 15 - 25 | 110 (26.5%) |
| 26 - 35 | 102 (24.6%) |
| 36 - 45 | 82 (19.8%) |
| 46 - 55 | 35 (8.4%) |
| 55+ | 86 (20.7%) |
| BMI |
|
| Mean (SD) | 25.79 (4.51) |
| Median (Q1, Q3) | 25.20 (22.52, 29.10) |
| Min - Max | 17.60 - 37.20 |
| ASA score |
|
| I | 227 (55.5%) |
| II | 152 (37.2%) |
| III | 27 (6.6%) |
| IV | 3 (0.7%) |
| Complications |
|
| no | 351 (84.6%) |
| yes | 64 (15.4%) |
| Aminoglycoside therapy |
|
| aminoglycoside therapy | 319 (76.9%) |
| no aminoglycoside therapy | 96 (23.1%) |
| Aminoglycoside therapy duration |
|
| Mean (SD) | 3.04 (1.97) |
| Median (Q1, Q3) | 3.00 (1.00, 4.00) |
| Min - Max | 1.00 - 11.00 |